Adnectin CT-322 inhibits tumor growth and affects microvascular architecture and function in Colo205 tumor xenografts.
Antiangiogenesis has become a promising pillar in modern cancer therapy. This study investigates the antiangiogenic effects of the PEGylated Adnectin™, CT-322, in a murine Colo-205 xenograft tumor model. CT-322 specifically binds to and blocks vascular endothelial growth factor receptor (VEGFR-2). Adnectins are a novel class of targeted biologics engineered from the 10th domain of human fibronectin. CT-322 treated tumors exhibited a significant reduction in tumor growth of 69%, a 2.8 times lower tumor surface area and fewer necrotic areas. Control tumors showed a 2.36-fold higher microvessel density (MVD) and a 2.42 times higher vessel volume in corrosion casts. The vascular architecture in CT-322-treated tumors was characterized by a strong normalization of vasculature. This was quantified in corrosion casts of CT-322 treated tumors in which the intervascular distance (a reciprocal parameter indicative of vessel density) and the distance between two consecutive branchings were assessed, with these distances being 2.21 times and 2.37 times greater than in controls, respectively. Fluorescence molecular tomography (FMT) equally affirmed the inhibitory effects of CT-322 on tumor vasculature as indicated by a 60% reduction of the vascular probe, AngioSense, accumulating in tumor tissue, as a measurement of vascular permeability. Moreover, AngioSense accumulation was reduced as early as 24 h after starting treatment. The sum of these effects on tumor vasculature illustrates the anti-angiogenic mechanism underlying the antitumor activity of CT-322 and provides support for further evaluation of this Adnectin in combinatorial strategies with standard of care therapies.
Institute of Functional & Clinical Anatomy, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Maximilian
M
Ackermann
Irvith M
IM
Carvajal
Brent A
BA
Morse
Miguel
M
Moreta
Steven
S
O'Neil
Sylvie
S
Kossodo
Jeffrey D
JD
Peterson
Vera
V
Delventhal
H Nicholas
HN
Marsh
Eric S
ES
Furfine
Moritz A
MA
Konerding
D000818:Animals; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D005260:Female; D005353:Fibronectins / Q000494:pharmacology*; D006801:Humans; D007668:Kidney / Q000098:blood supply; D051379:Mice; D008819:Mice, Nude; D008855:Microscopy, Electron, Scanning; D055806:Microvessels / Q000187:drug effects; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000473:pathology; D010446:Peptide Fragments / Q000494:pharmacology*; D016896:Treatment Outcome; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors; D023041:Xenograft Model Antitumor Assays
C549678:CT-322; D005353:Fibronectins; D010446:Peptide Fragments; D040301:Vascular Endothelial Growth Factor Receptor-2